MX2022013429A - Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico. - Google Patents

Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.

Info

Publication number
MX2022013429A
MX2022013429A MX2022013429A MX2022013429A MX2022013429A MX 2022013429 A MX2022013429 A MX 2022013429A MX 2022013429 A MX2022013429 A MX 2022013429A MX 2022013429 A MX2022013429 A MX 2022013429A MX 2022013429 A MX2022013429 A MX 2022013429A
Authority
MX
Mexico
Prior art keywords
compositions
25hc3s
cholesten
diol
sulfate
Prior art date
Application number
MX2022013429A
Other languages
English (en)
Inventor
Shunlin Ren
Jin Koung Kim
Wilma Tamraz
Weiqi Lin
Leyuan Xu
Yanxia Ning
Mee Jean Kim
Andrew R Miksztal
Hongwei Wu
Min L Lee
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of MX2022013429A publication Critical patent/MX2022013429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporcionan composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25HC3S), o una sal farmacéuticamente aceptable del mismo, y por lo menos un oligosacárido cíclico, por ejemplo, una ciclodextrina (CD). Las composiciones se pueden utilizar para la prevención y/o el tratamiento de una variedad de enfermedades y afecciones, con la inclusión de la falla de órganos (por ejemplo, una falla aguda del hígado), colesterol alto / lípidos altos, y diferentes enfermedades y afecciones inflamatorias.
MX2022013429A 2016-08-02 2019-01-30 Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico. MX2022013429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370024P 2016-08-02 2016-08-02
US201762470578P 2017-03-13 2017-03-13

Publications (1)

Publication Number Publication Date
MX2022013429A true MX2022013429A (es) 2022-11-14

Family

ID=61073854

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001323A MX2019001323A (es) 2016-08-02 2017-08-01 Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
MX2022013429A MX2022013429A (es) 2016-08-02 2019-01-30 Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019001323A MX2019001323A (es) 2016-08-02 2017-08-01 Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.

Country Status (22)

Country Link
US (4) US20190269695A1 (es)
EP (2) EP4101861A1 (es)
JP (3) JP2019524772A (es)
KR (3) KR102593667B1 (es)
CN (2) CN116747233A (es)
AU (2) AU2017305239C1 (es)
CA (1) CA3031224A1 (es)
DK (1) DK3494125T3 (es)
EA (1) EA201990438A1 (es)
ES (1) ES2922933T3 (es)
HR (1) HRP20220932T1 (es)
HU (1) HUE059768T2 (es)
IL (2) IL298681A (es)
LT (1) LT3494125T (es)
MX (2) MX2019001323A (es)
PL (1) PL3494125T3 (es)
PT (1) PT3494125T (es)
RS (1) RS63529B1 (es)
SI (1) SI3494125T1 (es)
SM (1) SMT202200330T1 (es)
TW (2) TW202426000A (es)
WO (1) WO2018026781A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP3086793B1 (en) 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
KR102593667B1 (ko) * 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
WO2021067297A1 (en) * 2019-09-30 2021-04-08 Durect Corporation Treatment of alcoholic hepatitis
CA3170320A1 (en) * 2020-02-11 2021-08-19 Durect Corporation Treatment of infectious diseases
US12478603B2 (en) 2020-03-31 2025-11-25 The Regents Of The University Of Michigan Serum metabolites as biomarkers for carnitine treatment of sepsis
EP4153164A4 (en) * 2020-05-22 2024-06-26 Durect Corporation TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
TW202216164A (zh) * 2020-06-26 2022-05-01 美商杜瑞克公司 氧合膽固醇硫酸酯用於治療自體免疫疾病之用途
CN112967234B (zh) * 2021-02-09 2022-12-09 复旦大学附属中山医院 冠状动脉功能生理学病变模式定量评价方法
US20240425545A1 (en) * 2021-06-25 2024-12-26 Durect Corporation 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same
CN113750039B (zh) * 2021-10-26 2023-08-18 浙江中医药大学 一种黄芩苷-海藻酸钙温敏纳米凝胶、制备方法及其应用
WO2023196412A1 (en) * 2022-04-06 2023-10-12 Nobias Therapeutics, Inc. Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same
CN119896674A (zh) * 2023-10-27 2025-04-29 上海交通大学医学院附属新华医院 胆固醇硫酸酯在制备治疗特应性皮炎的药物中的应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
BE794362A (fr) 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3928397A (en) 1973-03-02 1975-12-23 Eisai Co Ltd New 5-cholestene derivatives and preparation thereof
US3822254A (en) 1973-05-21 1974-07-02 Hoffmann La Roche Synthesis of 25-hydroxycholesterol
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4202891A (en) 1977-05-16 1980-05-13 Kandutsch Andrew A 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols
GB1595020A (en) 1977-06-24 1981-08-05 Chugai Pharmaceutical Co Ltd 3a-hydroxy steroid derivatives of the cholestane series
US4427668A (en) 1982-04-01 1984-01-24 New York University 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5510340A (en) 1992-06-12 1996-04-23 Sri International Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
US5371077A (en) 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them
US5599659A (en) 1993-03-11 1997-02-04 Breonics, Inc. Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate
US5587368A (en) * 1993-11-30 1996-12-24 New York University Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
RU2182909C2 (ru) 1995-06-23 2002-05-27 Ново Нордиск А/С Стероиды, способ регулирования мейоза
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
IL139241A0 (en) 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
DE69913513T2 (de) 1998-05-13 2004-09-30 Novo Nordisk A/S Verwendung von verbindungen mit der fähigkeit die meiose zu regulieren
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060025393A1 (en) 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
IL146223A0 (en) 1999-04-30 2002-07-25 Arch Dev Corp Steroid derivatives
AU1291901A (en) 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
JP4018312B2 (ja) 2000-02-21 2007-12-05 株式会社ルネサステクノロジ 無線通信装置
IN191090B (es) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
CN1498222A (zh) * 2001-02-08 2004-05-19 芝加哥大学 类固醇衍生物
US20020164310A1 (en) 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
DK1392713T3 (da) 2001-05-03 2008-02-18 Univ Chicago Lever-X-receptoragonister
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP1450816A4 (en) 2001-11-08 2008-02-13 Univ Chicago METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE
GEP20063996B (en) * 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
KR101286969B1 (ko) 2004-06-30 2013-07-23 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US8044243B2 (en) 2006-02-13 2011-10-25 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
DE102006021181B3 (de) 2006-05-06 2007-05-03 Laux, Thomas, Dr. Zahnprothesen-Trägerimplantat
GB0625965D0 (en) 2006-12-23 2007-02-07 Renovo Ltd Medicaments for wound healing
WO2009002873A1 (en) 2007-06-22 2008-12-31 Cvi Pharmaceuticals Limited Compounds, compositions and methods for reducing lipid levels
US8831674B2 (en) 2007-09-27 2014-09-09 Multi-Tech Systems, Inc. Message server
JP5188583B2 (ja) 2008-01-04 2013-04-24 エルジー・ライフ・サイエンシーズ・リミテッド 細胞、組織及び臓器保存効果を有するインドール及びインダゾール誘導体
WO2011077245A2 (en) 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
EP2608781A4 (en) * 2010-08-04 2014-01-29 Tixupharma INCLUSION COMPLEXES OF CYCLODEXTRINS WITH SPERMIDINE AND PROLIFERATIVE BZW. REPAIR COMPOSITIONS THEREWITH
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN106083976B (zh) 2012-04-12 2018-02-09 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)
CN104768615B (zh) 2012-07-17 2019-02-22 密执安大学评议会 治疗白内障的非手术方法
CA2880880C (en) 2012-08-03 2021-01-26 John Mckew Cyclodextrin for the treatment of lysosomal storage diseases
US20140220112A1 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
EP2842547A1 (en) * 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
EP3086793B1 (en) * 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
EP3204011A4 (en) * 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
EP3204013A1 (en) * 2014-10-10 2017-08-16 Virginia Commonwealth University Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder
JP2018522070A (ja) 2015-07-27 2018-08-09 キャタコア・インコーポレイテッドＣａｔａｃｏｒｅ， Ｉｎｃ． 白内障の処置用組成物
US20190374554A1 (en) 2016-08-02 2019-12-12 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
WO2018026837A1 (en) 2016-08-02 2018-02-08 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
WO2021067297A1 (en) 2019-09-30 2021-04-08 Durect Corporation Treatment of alcoholic hepatitis
US20230056273A1 (en) 2019-12-27 2023-02-23 Durect Corporation Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
CA3170320A1 (en) 2020-02-11 2021-08-19 Durect Corporation Treatment of infectious diseases
JP2023526418A (ja) 2020-05-22 2023-06-21 デュレクト コーポレーション 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置
EP4153164A4 (en) 2020-05-22 2024-06-26 Durect Corporation TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
TW202216164A (zh) 2020-06-26 2022-05-01 美商杜瑞克公司 氧合膽固醇硫酸酯用於治療自體免疫疾病之用途

Also Published As

Publication number Publication date
US12226423B2 (en) 2025-02-18
CN109983025B (zh) 2023-04-04
EP4101861A1 (en) 2022-12-14
AU2017305239A1 (en) 2019-02-21
TW202426000A (zh) 2024-07-01
TWI815796B (zh) 2023-09-21
HUE059768T2 (hu) 2022-12-28
US20210169898A1 (en) 2021-06-10
IL264390B (en) 2022-12-01
EA201990438A1 (ru) 2019-08-30
IL264390A (en) 2019-02-28
CA3031224A1 (en) 2018-02-08
US20190269695A1 (en) 2019-09-05
WO2018026781A1 (en) 2018-02-08
JP7487264B2 (ja) 2024-05-20
AU2017305239C1 (en) 2022-08-18
DK3494125T3 (da) 2022-08-01
PL3494125T3 (pl) 2022-10-17
AU2022204217B2 (en) 2024-04-04
US11406646B2 (en) 2022-08-09
TW201818945A (zh) 2018-06-01
KR102465046B1 (ko) 2022-11-10
IL298681A (en) 2023-01-01
SI3494125T1 (sl) 2022-10-28
SMT202200330T1 (it) 2022-11-18
MX2019001323A (es) 2019-07-04
US20230047788A1 (en) 2023-02-16
IL264390B2 (en) 2023-04-01
HRP20220932T1 (hr) 2022-10-28
JP2024105442A (ja) 2024-08-06
AU2017305239B2 (en) 2022-03-17
JP2019524772A (ja) 2019-09-05
KR20230152787A (ko) 2023-11-03
CN109983025A (zh) 2019-07-05
ES2922933T3 (es) 2022-09-21
KR20220154250A (ko) 2022-11-21
US20250249021A1 (en) 2025-08-07
EP3494125A1 (en) 2019-06-12
EP3494125B1 (en) 2022-06-22
EP3494125A4 (en) 2020-04-01
CN116747233A (zh) 2023-09-15
KR20190035776A (ko) 2019-04-03
LT3494125T (lt) 2022-11-10
JP2022169550A (ja) 2022-11-09
AU2022204217A1 (en) 2022-07-07
KR102593667B1 (ko) 2023-10-24
RS63529B1 (sr) 2022-09-30
PT3494125T (pt) 2022-07-07

Similar Documents

Publication Publication Date Title
MX2022013429A (es) Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
MX2020011537A (es) Esteroides neuroactivos, composiciones y uso de los mismos.
MX2022003896A (es) Esteroides neuroactivos, composiciones y usos de los mismos.
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
MX391441B (es) Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.
EP4553082A3 (en) Liver organoid compositions and methods of making and using same
AU2018270408A1 (en) Methods of inhibiting aging and treating aging-related disorders
EP4591935A3 (en) Methods for the preparation of ribosides
BR112013002601A2 (pt) corticosteróides para o tratamento de dor em articulação
MX387667B (es) Composiciones corticosteroides.
WO2015184257A3 (en) Small molecule transcription modulators of bromodomains
BR112015031278A8 (pt) compostos e nanopartículas de platina com base em lipídio
EA201790884A1 (ru) 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA201790791A1 (ru) Сульфаты окисленного холестерина, используемые для лечения расстройств, вызываемых по меньшей мере одним из состояний, связанных с пониженной лептиновой активностью и накоплением липидов
MX2019001324A (es) Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel.
MX2010002559A (es) Composiciones y metodos para tratar enfermedades y desordenes inmulogicos e inflamatorios.
CY1122827T1 (el) Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους
WO2016081701A3 (en) CDDO-Me AS A THERAPY FOR LUPUS
EP4603097A3 (en) Mucoadhesive pharmaceutical compositions of corticosteroids
EA201990437A1 (ru) Композиции, содержащие по меньшей мере один окисленный холестеринсульфат и по меньшей мере одно из полиалкиленгликоля, карбоксиметилцеллюлозы и полиоксилглицерида, и способы их применения
HK1235002A1 (en) Neuroactive steroids, compositions, and uses thereof
HK40062174A (en) Methods and compositions for cluster generation by bridge amplification
UA121198U (uk) Композиція для лікування і профілактики захворювань печінки
CN302510437S (zh) 配电柜（低压配电柜闸刀后大门）
NZ620005A (en) Pharmaceutical composition comprising ebastine and fluticasone